Citations

Mayo Clinic

Showing 10 of 108523 citations.

A Comprehensive Review on the Intricate Interplay between COVID-19 Immunization and the New Onset of Pemphigus Foliaceus
Bălăceanu-Gurău, Beatrice , Dumitrascu, Adrian , Giurcăneanu, Călin , Tătar, Raluca , Gurău, Cristian-Dorin , Orzan, Olguța Anca , Dumitrascu, Adrian George

Vaccines | July 31, 2024 | Volume: 12 | Issue: 8 | Pages: 857

10.3390/vaccines12080857 | PMID 39203983 Get It

Autoimmune bullous diseases (AIBDs) are characterized by the formation of vesicles, bullous lesions, and mucosal erosions. The autoantibodies target the cellular anchoring structures from the surface of epidermal keratinocyte named desmosomes, leading to a loss of cellular cohesion named acantholysis. AIBDs are classified into intraepidermal or subepidermal types based on clinical features, histological characteristics, and immunofluorescence patterns. Pemphigus foliaceus (PF) is an acquired, rare, autoimmune skin condition associated with autoantibodies that specifically target desmoglein-1, leading to a clinical presentation characterized by delicate cutaneous blisters, typically sparing the mucous membranes. Several factors, including genetic predisposition, environmental triggers, malignancies, medication use, and vaccination (for influenza, hepatitis B, rabies, tetanus, and more recently, severe acute respiratory syndrome Coronavirus 2 known as SARS-CoV-2), can potentially trigger the onset of pemphigus. With the advent of vaccines playing a pivotal role in combatting the 2019 coronavirus disease (COVID-19), extensive research has been conducted globally to ascertain their efficacy and potential cutaneous adverse effects. While reports of AIBDs post-COVID-19 vaccination exist in the medical literature, instances of PF following vaccination have been less commonly reported worldwide. The disease’s pathophysiology is likely attributed to the resemblance between the ribonucleic acid (RNA) antigen present in these vaccines and cellular nuclear matter. The protein produced by the BNT-162b2 messenger ribonucleic acid (mRNA) vaccine includes immunogenic epitopes that could potentially trigger autoimmune phenomena in predisposed individuals through several mechanisms, including molecular mimicry, the activation of pattern recognition receptors, the polyclonal stimulation of B cells, type I interferon production, and autoinflammation. In this review, we present a comprehensive examination of the existing literature regarding the relationship between COVID-19 and PF, delving into their intricate interactions. This exploration improves the understanding of both pemphigus and mRNA vaccine mechanisms, highlighting the importance of close monitoring for PF post-immunization.
A Contemporary Review of Blood Transfusion in Critically Ill Patients
Yadav, Sumeet K. , Hussein, Guleid , Liu, Bolun , Vojjala, Nikhil , Warsame, Mohamed , Labban, Mohamad El , Rauf, Ibtisam , Zareen, Tashfia, Zhang, Y , Jain, Shika M., Surani, Salim , Devulapally, Pavan , Bartlett, Brian, Khan, Syed Anjum , Jain, Nitesh , El Labban, Mohamad , Zhang, Yaqi , Surani, Salim , Devulapally, Pavan , Khan, Syed Anjum , Jain, Nitesh Kumar , Yadav, Sumeet Kumar , Liu, Bolun , Hassan, Mohamed Sayed , Usama, Syed Muhammad, Jain, Shika M

Medicina | July 31, 2024 | Volume: 60 | Issue: 8 | Pages: 1247

10.3390/medicina60081247 | PMID 39202529 Get It

Blood transfusion is a common therapeutic intervention in hospitalized patients. There are numerous indications for transfusion, including anemia and coagulopathy with deficiency of single or multiple coagulation components such as platelets or coagulation factors. Nevertheless, the practice of transfusion in critically ill patients has been controversial mainly due to a lack of evidence and the need to consider the appropriate clinical context for transfusion. Further, transfusion carries many risk factors that must be balanced with benefits. Therefore, transfusion practice in ICU patients has constantly evolved, and we endeavor to present a contemporary review of transfusion practices in this population guided by clinical trials and expert guidelines.
The artificial intelligence advantage: Supercharging exploratory data analysis
Oettl, Felix C. , Oeding, Jacob F. , Feldt, Robert , Ley, Christophe , Hirschmann, Michael T. , Samuelsson, Kristian , Group, ESSKA Artificial Intelligence Working, Oettl, Felix C. , Samuelsson, Kristian , Oeding, Jacob F , Hirschmann, Michael T , Feldt, Robert , Ley, Christophe , Group, ESSKA Artificial Intelligence Working

Knee Surgery, Sports Traumatology, Arthroscopy | July 31, 2024 | Volume: 32 | Issue: 11 | Pages: 3039-3042

10.1002/ksa.12389 | PMID 39082872 Get It

Abstract Explorative data analysis (EDA) is a critical step in scientific projects, aiming to uncover valuable insights and patterns within data. Traditionally, EDA involves manual inspection, visualization, and various statistical methods. The advent of artificial intelligence (AI) and machine learning (ML) has the potential to improve EDA, offering more sophisticated approaches that enhance its efficacy. This review explores how AI and ML algorithms can improve feature engineering and selection during EDA, leading to more robust predictive models and data‐driven decisions. Tree‐based models, regularized regression, and clustering algorithms were identified as key techniques. These methods automate feature importance ranking, handle complex interactions, perform feature selection, reveal hidden groupings, and detect anomalies. Real‐world applications include risk prediction in total hip arthroplasty and subgroup identification in scoliosis patients. Recent advances in explainable AI and EDA automation show potential for further improvement. The integration of AI and ML into EDA accelerates tasks and uncovers sophisticated insights. However, effective utilization requires a deep understanding of the algorithms, their assumptions, and limitations, along with domain knowledge for proper interpretation. As data continues to grow, AI will play an increasingly pivotal role in EDA when combined with human expertise, driving more informed, data‐driven decision‐making across various scientific domains. Level of Evidence: Level V ‐ Expert opinion.
Review article: Oesophageal disorders in chronic liver disease
Idalsoaga, Francisco , Díaz, Luis Antonio , Ayares, Gustavo , Cabrera, Daniel , Chahuán, Javier , Monrroy, Hugo , Halawi, Houssam , Arrese, Marco , Arab, Juan P , Díaz, Luis A , Ayares, Gustavo , Arrese, Marco , Chahuan, Javier , Monrroy, Hugo , Halawi, Houssam , Arab, Juan Pablo

Alimentary Pharmacology & Therapeutics | July 31, 2024 | Volume: 60 | Issue: 6 | Pages: 715-726

10.1111/apt.18193 | PMID 39082463 Get It

Summary Background Oesophageal disorders and chronic liver disease are common worldwide and significantly impact quality of life. The intricate link between these conditions, including how oesophageal disorders like GERD, Barrett's oesophagus and oesophageal cancer affect and are affected by chronic liver disease, remains poorly understood. Aims To review the relationship between oesophageal disorders and chronic liver disease, evaluating epidemiology, pathophysiology and therapeutic factors. Methods We reviewed the literature on the relationship between oesophageal disorders and chronic liver disease, including cirrhosis, using the PubMed database Results Oesophageal disorders such as gastroesophageal reflux disease, Barrett's oesophagus, oesophageal cancer, oesophageal motor disorders and oesophageal candidiasis are prevalent among individuals with cirrhosis, exacerbating the burden of liver disease. These diseases have a multifaceted symptomatology and pathogenic basis, posing a significant challenge in cirrhotic patients that necessitates careful diagnosis and management. Additionally, therapies frequently used for these diseases, such as proton pump inhibitors, require careful consideration in cirrhotic patients due to potential adverse effects and altered pharmacokinetics. Managing oesophageal disorders in cirrhotic patients requires a cautious approach due to possible interactions with medications and the risk of adverse effects. Furthermore, symptoms associated with these conditions are often exacerbated by common interventions in patients with cirrhosis, such as band ligation for oesophageal varices. Conclusions Oesophageal disorders are common in cirrhosis and increase the disease burden. These conditions require careful management due to complex symptoms and treatment risks. Proton pump inhibitors and other therapies must be used cautiously, as cirrhosis interventions can worsen symptoms.
Incidence and Long-Term Outcomes of Biliary Tract Cancers in Olmsted County, Minnesota from 1976 to 2018
Nwankwo, Eugene , Guta, Amerti, Cao, Scarlett , Yang, Ju Dong , Abdalla, Abubaker , Taha, Wesam, Larson, Joseph J. , Yin, Jun , Gores, Gregory J. , Roberts, Lewis R. , Gores, Gregory J. , Nwankwo, Eugene C, Cao, Scarlett S , Roberts, Lewis R , Yang, Ju Dong , Cleary, Sean P.

Cancers | July 31, 2024 | Volume: 16 | Issue: 15 | Pages: 2720

10.3390/cancers16152720 | PMID 39123448 Get It

Biliary tract cancers, including cholangiocarcinoma, gallbladder, and ampulla of Vater cancers, rank second among hepatobiliary cancers, known for their poor prognoses. The United States has witnessed a notable increase in intrahepatic cholangiocarcinoma incidence. This study examines the incidence and survival outcomes of biliary tract cancers in Olmsted County, Minnesota from 1976 to 2018. Using data from the Rochester Epidemiology Project (REP), residents aged 20 and above were analyzed across four eras. Incidence rates were calculated and adjusted for age and sex, and temporal trends were assessed using Poisson regression. Intrahepatic cholangiocarcinoma exhibited a significant escalation in incidence rates over time, while gallbladder cancers showed a decline among women. Median survival times for biliary tract cancers notably improved. These findings confirm the rising incidence of intrahepatic cholangiocarcinoma and suggest improving survival rates. Nevertheless, the overall prognosis for biliary tract cancers remains very poor, emphasizing the continual need for enhanced management strategies and further research.
Evaluation of Cannabis-Related Product Use Among Patients With Hidradenitis Suppurativa: A Narrative Review
Shojaei, Delaram , Zabihi, Haleh , Maida, Vincent , Kirchhof, Mark G. , Alavi, Afsáneh

Journal of Cutaneous Medicine and Surgery | July 31, 2024 | Volume: 28 | Issue: 5 | Pages: 481-485

10.1177/12034754241266125 | PMID 39082368 Get It

The use of cannabis and cannabis-related products among patients with hidradenitis suppurativa (HS) is increasing globally. Given the potential anti-inflammatory, therapeutic, and pain management benefits of cannabis-related products, we reviewed primary literature to evaluate the prevalence and possible purpose for cannabis use among patients with HS and to provide recommendations to patients and physicians. A narrative review of original studies was conducted using Embase and Ovid Medline databases. The search strategy was confirmed by a librarian and conducted on September 1, 2023, using a detailed list of subject headings and keywords tailored to cannabis, cannabis-related products, HS, and both adult and pediatric populations. Among 43 identified studies, 6 met the eligibility criteria and encompassed 34,435 patients. Patients were mostly female, and studies were conducted across the United States, Canada, and France. Findings show higher cannabis use among HS patients, demonstrating efficacy in pain management, sleep, anxiety relief, itch relief, and improved quality of life. Cannabis may play a role in analgesia, improved quality of life, pain, itch, and overall mental health in patients with HS and healthcare providers including dermatologists should increase their familiarity in appropriate use of cannabis-related products.
A novel structured, volume‐based, weight‐loss and health programme combined with respiratory muscle training helps reduce weight and cardiovascular risk in people with obesity
Woodard, J., Boeder, MiKinze, Turinske, Thomas J., Stiles, Ashley, Lipset, Max, Bausek, Nina , Bausek, Nina , Woodard, Jacob, Meyer, Nicholas J.

Diabetes, Obesity and Metabolism | July 31, 2024 | Volume: 26 | Issue: 10 | Pages: 4772-4775

10.1111/dom.15795 | PMID 39082073 Get It

Clinicopathologic correlates and prognostic impact of lymphoid aggregates in patients with myelodysplastic syndromes
Baranwal, Anmol , Shah, Meera , Shi, Min , Reichard, Kaaren K. , Gangat, Naseema , Patnaik, Mrinal M. , Begna, Kebede H. , Litzow, Mark R. , Tefferi, Ayalew , Al‐Kali, Aref , Mangaonkar, Abhishek A. , Shah, Mithun V , Greipp, Patricia, Shi, Min , Gangat, Naseema , Alkhateeb, Hassan B , Tefferi, Ayalew , Al-Kali, Aref , Mangaonkar, Abhishek A. , Baranwal, Anmol , Greipp, Patricia T. , Jevremović, Dragan , Alkhateeb, Hassan B. , Hogan, William J.

British Journal of Haematology | July 31, 2024 | Volume: 205 | Issue: 4 | Pages: 1627-1631

10.1111/bjh.19677 | PMID 39081199 Get It

Pharmacologic Efficacy in Neuropsychiatry
Rummans, Teresa A. , Lauterbach, Edward C., Coffey, C. Edward, Royall, Donald R. , Salloway, Stephen , Duffy, James , Kaufer, Daniel , Cummings, Jeffrey L. , Duffy, James

The Journal of Neuropsychiatry and Clinical Neurosciences | July 31, 2024 | Volume: 11 | Issue: 2 | Pages: 176-189

10.1176/jnp.11.2.176 | PMID 10333990 Get It

Characterizing heart failure and its subtypes in people living with HIV
Inestroza, Karla , Hurtado, Vanessa , Larson, Michaela E. , Severdija, Ryan, Lang, Barbara, Jones, Deborah L. , Martinez, Claudia , Inestroza, Karla , Satish, Sanjana , Ebner, Bertrand , Alcaide, Maria Luisa

HIV Medicine | July 31, 2024 | Volume: 25 | Issue: 12 | Pages: 1298-1307

10.1111/hiv.13694 | PMID 39081068 Get It

Abstract Objective People living with HIV have an increased risk of heart failure (HF). There are different subtypes of HF. Knowledge about the factors differentiating HF subtypes in people with HIV is limited but necessary to guide preventive measures and treatment. Methods A retrospective review of medical records was undertaken in people with HIV aged ≥18 years who received care at the University of Miami/Jackson Memorial HIV Clinic between January 2017 and November 2019 ( N = 1166). Patients with an echocardiogram available for review ( n = 305) were included. HF was defined as a documented diagnosis of any HF subtype ( n = 52). We stratified those with HF by their ejection fraction (EF) into HF with preserved EF (HFpEF), HF with borderline EF, or HF with reduced EF (HFrEF). Results The prevalence of HF was 4.5%. The cohort included 46.2% females and 75% self‐identified African Americans. Those with HF had a higher prevalence of hypertension, prior myocardial infarction, angina, coronary artery disease, percutaneous coronary intervention, coronary artery bypass grafting, diastolic dysfunction, and left ventricle hypertrophy. People with HIV with HF with borderline EF exhibited more coronary artery disease than those with HFpEF. Conclusions We characterize HF in people with HIV in South Florida and report the prevalence of HF and HF subtypes. Only a small percentage of patients had echocardiograms performed, suggesting an ongoing need for recognition of the increased risk of HF in people living with HIV, and raising the concern about lack of awareness contributing to underdiagnosis and missed treatment opportunities in this population.